Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | GFER | P55789 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6193842 | 0.93 | POLB (0.38) | KMT2AMEN1GFERTSHRMAPK1 | |
| SCHEMBL6194581 | 0.90 | CTSB (0.41) | KMT2AMEN1CTSKDRD3DRD2 | |
| SCHEMBL6193510 | 0.89 | DRD3 (0.49) | KMT2AMEN1TRPV1DRD3DRD2 | |
| SCHEMBL6192611 | 0.88 | KMT2A (0.41) | KMT2AMEN1TSHRDRD3DRD2 | |
| SCHEMBL6192220 | 0.88 | DRD3 (0.39) | KMT2AMEN1DRD3DRD2HTR1A | |
| SCHEMBL6192678 | 0.88 | DRD3 (0.44) | GFERTSHRMAPK1DRD3DRD2 | |
| SCHEMBL6192402 | 0.87 | LMNA (0.41) | KMT2AMEN1TSHRDRD3DRD2 | |
| SCHEMBL6195525 | 0.87 | RAB9A (0.41) | KMT2AMEN1TSHRDRD3DRD2 | |
| SCHEMBL6194049 | 0.87 | DRD2 (0.39) | DRD2HTR2CRIPK1 | |
| SCHEMBL6193548 | 0.84 | NAMPT (0.39) | KMT2AMEN1TSHRCTSKHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432701-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI IRELAND LTD (IE) | 2005-12-21 | — | — | EP | claimed |
| EP-1432701-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 2004-06-30 | — | — | EP | claimed |
| US-20030181446-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-09-25 | — | — | US | claimed |
| WO-2003031436-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. (CH) | 2003-04-17 | — | — | WO | claimed |
| EP-1432701-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI IRELAND LTD (IE) | 2005-12-21 | — | — | EP | disclosed |
| EP-1432701-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 2004-06-30 | — | — | EP | disclosed |
| US-20030181446-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-09-25 | — | — | US | disclosed |
| US-20030162777-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-08-28 | — | — | US | disclosed |
| WO-2003031436-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. (CH) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162777-A1 | Novel N-acylated heterocycles | HTR1A, HTR1D, HTR1E | KMT2A 2287/4885MEN1 1822/4885GFER 693/4885 |
| US-20030181446-A1 | Novel N-acylated heterocycles | HTR1A, HTR1E, HTR2C | KMT2A 3319/4885MEN1 2190/4885GFER 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.